Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Allergy, Asthma & Clinical Immunology
Published in: Allergy, Asthma & Clinical Immunology 1/2015

Open Access 01-12-2015 | Review

Insights and advances in chronic urticaria: a Canadian perspective

Authors: Gordon Sussman, Jacques Hébert, Wayne Gulliver, Charles Lynde, Susan Waserman, Amin Kanani, Moshe Ben-Shoshan, Spencer Horemans, Carly Barron, Stephen Betschel, William H Yang, Jan Dutz, Neil Shear, Gina Lacuesta, Peter Vadas, Kenneth Kobayashi, Hermenio Lima, F Estelle R Simons

Published in: Allergy, Asthma & Clinical Immunology | Issue 1/2015

Login to get access

Abstract

In the past few years there have been significant advances which have changed the face of chronic urticaria. In this review, we aim to update physicians about clinically relevant advances in the classification, diagnosis and management of chronic urticaria that have occurred in recent years. These include clarification of the terminology used to describe and classify urticaria. We also detail the development and validation of instruments to assess urticaria and understand the impairment on quality-of-life and the morbidity caused by this disease. Additionally, the approach to management of chronic urticaria now focuses on evidence-based use of non-impairing, non-sedating H1-antihistamines given initially in standard doses and if this is not effective, in up to 4-fold doses. For urticaria refractory to H1-antihistamines, omalizumab treatment has emerged as an effective, safe option.
Literature
1.
Maurer M, Bindslev-Jensen C, Gimenez-Arnau A, Godse K, Grattan CEM, Hide M, et al. Chronic idiopathic urticaria is no longer idiopathic: time for an update! Br J Dermatol. 2013;168:455–6.CrossRefPubMed
2.
Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al. The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis and management of urticaria: the 2013 revision and update. Allergy. 2014;69:868–87.CrossRefPubMed
3.
Bernstein J, Lang D, Khan D, Craig T, Dreyfus D, Hsieh F, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133:1270–7.CrossRefPubMed
4.
Uguz F, Engin B, Yilmaz EJ. Axis I and Axis II diagnoses in patients with chronic idiopathic urticaria. J Psychosom Res. 2008;64:225–9.CrossRefPubMed
5.
Staubach P, Eckhardt-Henn A, Dechene M, Vovend A, Metz M, Magerl M, et al. Quality of life in patients with chronic urticarial is differentially impaired and determined by psychiatric comorbidity. Br J Dermatol. 2006;154:294–8.CrossRefPubMed
6.
Ben-Shoshan M, Blinderman I, Raz A. Psychosocial factors and chronic spontaneous urticaria: a systematic review. Allergy. 2013;68:131–41.CrossRefPubMed
7.
Rabelo-Filardi R, Daltro-Oliveira R, Campos RA. Parameters associated with chronic spontaneous urticaria duration and severity: a systematic review. Int Arch Allergy Immunol. 2013;161:197–204.CrossRefPubMed
8.
Baiardini I, Pasquali M, Braido F, Fumagali F, Guerra L, Compalati E, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL). Allergy. 2005;60:1073–8.CrossRefPubMed
9.
Weller K, Groffik A, Magerl M, Tohme N, Martus P, Krause K, et al. Development, validation and initial results of the Angioedema Activity Score. Allergy. 2013;68:1185–92.PubMed
10.
Weller K, Groffik A, Church M, Hawro T, Krause K, Metz M, et al. Development and validation of the urticaria control test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol. 2014;133:1365–72.CrossRefPubMed
11.
Simons FER, Simons KJ. Histamine and H1-antihistamines: celebrating a century of progress. J Allergy ClinImmunol. 2011;128:1139–50.CrossRef
12.
Kavosh ER, Khan DA. Second-generation H1-antihistamines in chronic urticaria: an evidence-based review. Am J ClinDermatol. 2011;12:361–76.
13.
Staevska M, Popov TA, Kralimarkova T, Lazarova C, Kraeva S, Popova D, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy ClinImmunol. 2010;125:676–82.CrossRef
14.
Weller K, Ardelean E, Scholz E, Martus E, Zuberbier T, Maurer M. Can on-demand non-sedating antihistamines improve urticaria symptoms? A double-blind, randomized, single-dose study. Acta Derm Venereol. 2013;93:168–74.CrossRefPubMed
15.
Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Treatment of recalcitrant chronic urticaria with nonsedating antihistamines: is there evidence for updosing? J Investig Allergol Clin Immunol. 2013;23:141–4.PubMed
16.
Church MK, Maurer M, Simons FER, Bindsley-Jensen C, van Cauwenberge P, Bousquet J, et al. Risks of first-generation H1-antihistamines: a GA2LEN position paper. Allergy. 2010;65:459–66.CrossRefPubMed
17.
Khan DA. Alternative agents in refractory chronic urticaria: evidence and considerations on their selection and use. J Allergy ClinImmunol Pract. 2013;1:433–40.CrossRef
18.
Fedorowicz Z, van Zuuren EJ, Hu N. Histamine H2-receptor antagonists for urticaria. Cochrane Database Syst Rev. 2012;3:CD008596.PubMed
19.
Asero R, Tedeschi A. Usefulness of a short course of oral prednisone in antihistamine-resistant chronic urticaria: a retrospective analysis. J Investig Allergol Clin Immunol. 2010;20:386–90.PubMed
20.
Maurer M, Rosen K, Hsieh Hsin J, Saini S, Grattan C, Gimenez-Arnau A, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924–35.CrossRefPubMed
21.
Kaplan A, Ledford D, Ashby M, Canvin J, Zazzali J, Conner E, et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. J Allergy ClinImmunol. 2013;132:101–9.CrossRef
22.
Sussman G, Hebert J, Barron C, Bian J, Caron-Guay R-M, Laflamme S, et al. Real-life experiences with omalizumab for the treatment of chronic urticaria. Ann Allergy Asthma Immunol. 2014;112:170–4.CrossRefPubMed
23.
Saini SS, Bindsley-Jensen C, Maurer M, Grob JJ, Bulbul Baskan E, Bradley MS, et al. Efficacy and safety of Omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1-antihistamines: A randomized, placebo-controlled study. J Invest Dermatol 2014;in press.
24.
Lang DM. A critical appraisal of omalizumab as a therapeutic option for chronic refractory urticaria/angioedema. Ann Allergy Asthma Immunol. 2014;112:276–9.CrossRefPubMed
25.
Metz M, Ohanyan T, Church MK, Maurer M. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria. JAMA Dermatol. 2014;150:288–90.CrossRefPubMed
Metadata
Title
Insights and advances in chronic urticaria: a Canadian perspective
Authors
Gordon Sussman
Jacques Hébert
Wayne Gulliver
Charles Lynde
Susan Waserman
Amin Kanani
Moshe Ben-Shoshan
Spencer Horemans
Carly Barron
Stephen Betschel
William H Yang
Jan Dutz
Neil Shear
Gina Lacuesta
Peter Vadas
Kenneth Kobayashi
Hermenio Lima
F Estelle R Simons
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Allergy, Asthma & Clinical Immunology / Issue 1/2015
Electronic ISSN: 1710-1492
DOI
https://doi.org/10.1186/s13223-015-0072-2

Other articles of this Issue 1/2015

Allergy, Asthma & Clinical Immunology 1/2015 Go to the issue

Review

CSACI position statement: epinephrine auto-injectors and children < 15 kg

Research

Risk factors associated with asthma, atopic dermatitis and rhinoconjunctivitis in a rural Senegalese cohort

Research

T-cell phenotypes in chronic rhinosinusitis with nasal polyps in Japanese patients

Case report

Allergy to cooked, but not raw, peas: a case series and review

Case report

Allergy to sunflower seed and sunflower butter as proposed vehicle for sensitization

Research

Prevention of pruritus with ethyl-chloride in skin prick test: a double-blind placebo-controlled prospective study